Skip directly to content

Safety Information

TOVIAZ®(fesoterodine fumarate)

Indications and Clinical Use:

Toviaz is indicated for the treatment of patients with overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, or any combination of these symptoms.

Safety and efficacy in pediatric populations have not been established.


  • Urinary retention
  • Gastric retention
  • Uncontrolled narrow-angle glaucoma
  • Hypersensitivity to tolterodine L-tartrate, soya, peanuts, lactose

Relevant warnings and precautions:

  • increase in heart rate
  • interaction with potent CYP3A4 inhibitors (i.e., max of 4 mg)
  • patients at risk of gastric retention
  • patients at risk of urinary retention
  • patients with impaired hepatic function
  • angioedema
  • patients with myasthenia gravis
  • patients with controlled narrow-angle glaucoma
  • patients with impaired renal function (i.e., max of 4 mg for severe impairment)
  • contraception in women of childbearing potential
  • not recommended during breastfeeding

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information.

The product monograph is also available by calling 1-800-463-6001.

TOVIAZ ® C.P. Pharmaceuticals International C.V., owner/Pfizer Canada Inc., Licensee